基因表达标志物可分类类风湿关节炎患者对甲氨蝶呤无应答
研究基于类风湿关节炎药物研究队列,对42例EULAR良好应答者和43例无应答者的全血转录本进行分析,利用治疗前与治疗4周表达比值构建L2正则化逻辑回归分类器,预测6个月MTX无应答的AUC为0.78±0.11,优于临床协变量模型(0.63±0.06);无应答者治疗前及治疗4周I型干扰素信号通路基因显著富集。
要点
- 治疗前至治疗4周基因表达变化可早期分类MTX无应答,AUC 0.78±0.11。
- 该分类器优于仅含临床协变量的模型(AUC 0.63±0.06)。
- 无应答者治疗前及4周I型干扰素通路基因显著富集。
核心结论
- 治疗前与治疗4周基因表达变化可提供MTX应答的早期分类器,识别6个月内不太可能获益的患者。
研究设计与样本
- 从类风湿关节炎药物研究中选择即将开始MTX治疗的患者,42例6个月EULAR良好应答、43例无应答,分析全血转录本并采用监督机器学习预测EULAR无应答。
主要发现
- 基于治疗4周与治疗前log2表达差值的L2正则化逻辑回归分类器预测MTX无应答的ROC AUC为0.78±0.11。
- 仅含临床协变量(如基线疾病活动度、性别)的模型ROC AUC为0.63±0.06。
- 无应答者治疗前I型干扰素信号通路基因显著富集(P=2.8×10^-25),治疗4周后亦显著富集(P=4.9×10^-28)。
关键数值与推荐
- 采用EULAR应答标准在MTX治疗6个月时分类良好应答与无应答。
- 分类器性能以ROC AUC评估,基因表达分类器为0.78±0.11,临床协变量模型为0.63±0.06。
临床怎么用
- 对开始MTX治疗的RA患者,可考虑早期(治疗前至4周)监测基因表达标志物以识别可能无应答者并更快升级治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Approximately 30-40% of rheumatoid arthritis (RA) patients who are initially started on low-dose methotrexate (MTX) will not benefit from the treatment. To date, no reliable biomarkers of MTX inefficacy in RA have been identified. The aim of this study was to analyze whole blood samples from RA patients at 2 time points (pretreatment and 4 weeks following initiation of MTX), to identify gene expression biomarkers of the MTX response. METHODS: RA patients who were about to commence treatment with MTX were selected from the Rheumatoid Arthritis Medication Study. Using European League Against Rheumatism (EULAR) response criteria, 42 patients were categorized as good responders and 43 as nonresponders at 6 months following the initation of MTX treatment. Data on whole blood transcript expression were generated, and supervised machine learning methods were used to predict a EULAR nonresponse. Models in which transcript levels were included were compared to models in which clinical covariates alone (e.g., baseline disease activity, sex) were included. Gene network and ontology analysis was also performed. RESULTS: Based on the ratio of transcript values (i.e., the difference in log2 -transformed expression values between 4 weeks of treatment and pretreatment), a highly predictive classifier of MTX nonresponse was developed using L2-regularized logistic regression (mean ± SEM area under the receiver operating characteristic [ROC] curve [AUC] 0.78 ± 0.11). This classifier was superior to models that included clinical covariates (ROC AUC 0.63 ± 0.06). Pathway analysis of gene networks revealed significant overrepresentation of type I interferon signaling pathway genes in nonresponders at pretreatment (P = 2.8 × 10-25 ) and at 4 weeks after treatment initiation (P = 4.9 × 10-28 ). CONCLUSION: Testing for changes in gene expression between pretreatment and 4 weeks post-treatment initiation may provide an early classifier of the MTX treatment response in RA patients who are unlikely to benefit from MTX over 6 months. Such patients should, therefore, have their treatment escalated more rapidly, which would thus potentially impact treatment pathways. These findings emphasize the importance of a role for early treatment biomarker monitoring in RA patients started on MTX.
引用
- Plant D, Maciejewski M, Smith S, et al. Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019. PMID: 30615300. doi:10.1002/art.40810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。